Back

USFDA PHARMACEUTICAL
INSPECTION READINESS GUIDE

Do's & Don'ts — Verified FDA Regulatory Language

FDA does not inspect your facility — they inspect your systems, your data, and your culture.

Critical → Major → Minor → IBP (Industry Best Practice)
IOM 2025 (Feb 2026) · 21 CFR 210/211/Part 11 · FDA Data Integrity Guidance Dec 2018 · FDA 483 Response Guidance Mar 2026

Version: April 2026
Critical → Major → Minor → IBP (Industry Best Practice)
SYSTEMS | DATA | CULTURE

Regulatory Reference

Regulatory Sources

  • IOM 2025 Chapter 5 (fda.gov,updated Feb 17,2026)
  • 21 CFR 210/211/Part 11

Supporting Guidance

  • FDA Data Integrity Q & A (Dec 2018)
  • FDA Draft Guidance on 483 Responses (Mar 9, 2026, Docket FDA-2025-D-1504)

Statutory Authority

  • FD&C Act §704(a) (Inspection Authority)
  • §301(f) (Prohibited Acts)
  • 18 U.S.C. §1519

FDA Terminology — What the FDA Actually Says

Many pharmaceutical inspection consulting guides use terms that do not appear anywhere in FDA regulatory documents. This guide uses only the FDA's own words. The table below shows the corrections.

Common Term FDA Official Term FDA Source
Escort Firm's Representative IOM 2025, §5.5.9.3
Scribe Not in FDA Documents — IBP Only No FDA source
Front Room Firm Management / Quality Unit Representatives IOM 2025, §5.5.12; 21 CFR 211.22
Back Room / War Room Quality Control Unit 21 CFR 211.22(a)
Closing Conference Closing Meeting IOM 2025, §5.5.12.2
SME (Subject Matter Expert) Qualified Person /Personnel Per 21 CFR 211.25 21 CFR 211.25

Severity Classification Legend

CRITICAL

Directly grounded in an explicit regulatory requirement. Failure constitutes a CGMP violation observable on Form FDA 483. May contribute to OAI classification.

MAJOR

Based on a regulatory requirement, it commonly generates a Form FDA 483 observation. May contribute to VAI or OAI classification.

MINOR

Based on a regulatory requirement, it represents a less severe documentation or procedural gap. May generate an informal comment or softer observation.

IBP (Industry Best Practice)

Industry Best Practice — professional consensus that is NOT found in FDA regulatory documents. Explicitly labeled so readers can distinguish it from regulatory requirements.